Vote Scores
Filings read through

How funds voted at Intra-Cellular Therapies, Inc.

Filers reporting
544, year to 30 June 2025
Latest meeting on file
Meetings on file
2

In the year to 30 June 2025, 544 filers on Form N-PX reported votes at Intra-Cellular Therapies, Inc.. The votes fall in 2 meetings. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 805 marks to the ballot items, each with or against management. 66.0% of the marks are with management.

On say-on-pay, 253 of the 495 reporting filers that marked the item voted against management. This is 51.1% of the filers. Of the reported shares, 39.9% went against management. The median of the 3,794 companies on this site with a say-on-pay item is 8.1% of filers and 4.0% of reported shares.

At the meeting of 27 Mar 2025, 20 fund families have a say-on-pay position with management and 25 have a position against management.

By filers reporting in the year to 30 June 2025, Intra-Cellular Therapies, Inc. was number 905 of 11,807 companies with a page and votes in that year. The number of filers reporting at Intra-Cellular Therapies, Inc. rose by 4.4% from the year to 30 June 2024 to the year to 30 June 2025. At the companies on this site with filers in both years, the total of filers reporting rose by 4.1%. In all seasons on file, category DIRECTOR ELECTIONS is 12.1% of the vote records at Intra-Cellular Therapies, Inc.. At all companies on this site, it is 52.2%.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2025. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 27 Mar 2025

540 filers reported votes at this meeting in the year to 30 June 2025. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

  1. Item 1: Advisory vote on executive pay (say-on-pay)

    747 vote records from 522 filers. 253 of the 495 filers that marked the item voted against management. 27 filers gave no management mark.

    • Positions of 46 fund families
    • For 18
    • Against 27
    • Split or no vote 1
    • Against management 25
  2. Item 2: Advisory vote on pay tied to a merger or sale

    11 vote records from 10 filers. 7 of the 8 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of one fund family
    • Against 1
    • Against management 1
  3. Item 3: EXTRAORDINARY TRANSACTIONS: management items

    The company's items in this category are shown together, because filers word and number them differently.

    241 vote records from 133 filers. 0 of the 132 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 38 fund families
    • For 38
  4. Item 4: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    10 vote records from 9 filers. 1 of the 8 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 2 fund families
    • For 2
  5. Item 5: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    339 vote records from 159 filers. 12 of the 158 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 41 fund families
    • For 39
    • Against 2
    • Against management 2
  6. Item 6: Shareholder proposals (not separable from the filings)

    • Proposed by a security holder
    • Several categories

    Filers described these proposals in different words that the site could not match, so they are shown together.

    1 vote record from 1 filer. 1 of the 1 filer that marked the item voted against management.

Positions of the fund families at the meeting of 27 Mar 2025

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Intra-Cellular Therapies, Inc., meeting of 27 Mar 2025Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familySay-on-payMerger pay
AllianceBernsteinAgainst, against managementNo report
AllspringAgainst, against managementNo report
American CenturyAgainst, against managementNo report
BlackRock and iSharesForNo report
BNY MellonAgainst, against managementNo report
Brighthouse FundsAgainstNo report
Capital Group and American FundsSplitNo report
Charles SchwabForNo report
Columbia ThreadneedleAgainst, against managementNo report
DimensionalAgainst, against managementNo report
DWSAgainst, against managementNo report
EquitableAgainst, against managementNo report
FidelityAgainst, against managementNo report
First TrustAgainst, against managementNo report
Franklin TempletonForNo report
Goldman SachsAgainst, against managementNo report
Guggenheim and RydexAgainst, against managementNo report
Hartford FundsForNo report
InvescoForNo report
J.P. MorganAgainst, against managementAgainst, against management
Jackson National fundsForNo report
Janus HendersonAgainst, against managementNo report
John Hancock and ManulifeAgainst, against managementNo report
Lincoln FinancialAgainstNo report
Macquarie and Delaware FundsAgainst, against managementNo report
MassMutualForNo report
Morgan Stanley, Eaton Vance and CalvertAgainst, against managementNo report
NationwideForNo report
Natixis and Loomis SaylesForNo report
Neuberger BermanForNo report
Northern Trust and FlexSharesAgainst, against managementNo report
Nuveen and TIAAAgainst, against managementNo report
Pacific Life fundsForNo report
PGIM and PrudentialForNo report
PrincipalForNo report
ProShares and ProFundsAgainst, against managementNo report
Russell InvestmentsForNo report
SEIForNo report
State Street and SPDRForNo report
T. Rowe PriceAgainst, against managementNo report
TransamericaAgainst, against managementNo report
VanguardForNo report
Victory CapitalAgainst, against managementNo report
VirtusForNo report
VoyaAgainst, against managementNo report
WisdomTreeAgainst, against managementNo report

Every meeting on file

Meetings of Intra-Cellular Therapies, Inc., from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 2025540651.1%
year to 30 June 2024520413.3%

Say-on-pay, season by season

Say-on-pay at Intra-Cellular Therapies, Inc.: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 202554451.1%39.9%
year to 30 June 202452113.3%41.1%
Intra-Cellular Therapies, Inc. and the median of companies on this site, year to 30 June 2025
Say-on-payThis companyMedian of companies on this site
Filers against management51.1%8.1%
Reported shares against management39.9%4.0%

The median covers 3,794 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at Intra-Cellular Therapies, Inc. by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS40812.1%
SECTION 14A SAY-ON-PAY VOTES1,56546.3%
AUDIT-RELATED40712.0%
EXTRAORDINARY TRANSACTIONS2417.1%
COMPENSATION41912.4%
CORPORATE GOVERNANCE33910.0%

The record at the SEC

Each link loaded on .

Cite this page

Vote Scores. How funds voted at Intra-Cellular Therapies, Inc.. https://votescores.com/company/intra-cellular-therapies-inc/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of Intra-Cellular Therapies, Inc. are on file?
2 meetings are on file, from 14 Jun 2024 to 27 Mar 2025. 2 meetings have 20 or more reporting filers and have their own page.
Did filers report proposals from security holders at Intra-Cellular Therapies, Inc.?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2025. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. Intra-Cellular Therapies, Inc. reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Intra-Cellular Therapies, Inc., grouped by company. The name is the most common spelling among filers. The filers wrote the filings. Filings read through .